Skip to content
Austin Top 50
Author:
Tango Therapeutics Sub, Inc
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2026
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
April 15, 2026
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 6, 2026
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
March 5, 2026